Hôpital Avicenne — Clinical Trial Site

18 Registered trials

9 Currently recruiting

Organisation

Hôpital Avicenne

Location

Bobigny, France

Identifier

ORL-000005476

Address

125 rue de Stalingrad, 93000, France

Departments

Haematology
Hématologie
Hematology
Hépathologie
hépato gastro enterology/digestive oncology
Hépato-Gastroentérologie
Hepatogastroenterology
HGE
Infectious and Tropical Diseases
Medical oncology
ONCOLOGY
Pneumology
Service de Pneumologie
Service de Rhumatologie
Service des maladies infectieuses et tropicales
Unite de Recherche Clinique/ Centre de Recherche Clinique

Clinical trials at this site (18)

Search interface

CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) P… Pending

2024-516328-32-00 CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) 4
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP… Pending

2024-516570-30-00 Relapsed/refractory T-cell Acute Lymphoblastic Leukemia 4
A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard… Recruiting

2025-521634-29-00 Acute Myeloid Leukemia 5 2026-03-02
MODULO Recruiting

2024-515793-27-01 HIV 5 2025-04-30
Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n… Recruiting

2023-504086-23-00 Subjects with PBC with a non-optimal response to UDCA. 5 2025-03-27
A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting

2024-516109-21-00 Polycythaemia Vera (PV) 5 2024-12-09
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Ampullary adenocarcinoma 5 2024-09-24
A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus… Recruiting

2024-516150-22-00 HIV 4 2024-04-11
Testing immunotherapy for patients with liver cancer and moderatelyaltered liver functions Recruiting

2024-516443-57-00 Patients with Hepatocellular Carcinoma (HCC) and Child- 4 2023-10-11
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting

2023-510541-25-00 Relapsed/Refractory B-cell Malignancies 1 2023-10-09
A Phase 2 Study of CAL101 in Patients with Idiopathic Pulmonary Fibrosis Ended

2024-518339-12-00 Idiopathic Pulmonary Fibrosis 4 2025-07-08
STUDY AGORA-1 / ALFA 2100: Phase 2 on the combinaison of Gemtuzumab Ozogamicin witk gilteritinib in adult patients with acute myeloid leukem… Ended

2023-504176-25-00 Acute Myeloid Leukemia 9 2024-08-08
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Non Small Cell Lung Cancer 5 2019-07-22
OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN A… Ended

2024-516048-24-00 CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR I 4 2019-06-19
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended

2024-516996-34-00 oestrogen-receptor (ER)-positive HER2-negative breast c 5 2012-04-12
ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TARGETED TREATMENT INADEQUATE RESPO… Ended

2024-515600-39-00 Adults patients suffering from rheumatoid arthritis and 6 2018-01-23